$FNCH
Finch Therapeutics Group, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023040924 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $361.0K
YoY Change -100.0% -100.0% -87.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.740M $8.877M $8.164M
YoY Change -60.98% 8.73% 38.8%
% of Gross Profit
Research & Development $0.00 $203.0K $13.92M
YoY Change -100.0% -98.54% -0.29%
% of Gross Profit
Depreciation & Amortization $60.00K $57.00K $1.363M
YoY Change -95.73% -95.82% 121.63%
% of Gross Profit
Operating Expenses $3.781M $9.881M $22.99M
YoY Change -90.73% -57.02% 15.84%
Operating Profit -$3.781M -$9.881M -$22.63M
YoY Change -90.69% -56.33% 32.99%
Interest Expense $390.0K $420.0K -$65.00K
YoY Change 766.67% -746.15% -1028.57%
% of Operating Profit
Other Income/Expense, Net $1.365M $2.931M -$71.00K
YoY Change 422.99% -4228.17% -103.84%
Pretax Income -$2.416M -$6.950M -$22.70M
YoY Change -94.02% -69.38% 49.65%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.416M -$6.950M -$22.70M
YoY Change -94.02% -69.38% 49.65%
Net Earnings / Revenue -6288.09%
Basic Earnings Per Share -$1.51 -$4.33 -$14.31
Diluted Earnings Per Share -$1.51 -$4.33 -$477.1K
COMMON SHARES
Basic Shares Outstanding 1.605M 48.14M 47.56M
Diluted Shares Outstanding 1.605M 1.605M 1.586M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.80M $34.05M $104.7M
YoY Change -66.23% -67.47% -37.75%
Cash & Equivalents $28.80M $34.10M $104.7M
Short-Term Investments
Other Short-Term Assets $1.100M $2.448M $5.698M
YoY Change -79.34% -57.04% -13.89%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $174.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $29.92M $36.50M $110.5M
YoY Change -66.98% -66.98% -37.55%
LONG-TERM ASSETS
Property, Plant & Equipment $637.0K $732.0K $18.45M
YoY Change -96.31% -96.03% 0.64%
Goodwill $18.06M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $4.597M
YoY Change -100.0% -100.0% 13.76%
Total Long-Term Assets $29.57M $30.36M $117.8M
YoY Change -69.62% -74.22% 60.59%
TOTAL ASSETS
Total Short-Term Assets $29.92M $36.50M $110.5M
Total Long-Term Assets $29.57M $30.36M $117.8M
Total Assets $59.49M $66.86M $228.3M
YoY Change -68.35% -70.72% -8.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $357.0K $432.0K $1.013M
YoY Change -66.32% -57.35% -41.07%
Accrued Expenses $4.500M $9.143M $14.17M
YoY Change -64.7% -35.48% 171.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.879M $9.575M $15.18M
YoY Change -64.67% -36.94% 59.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $14.62M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $0.00 $0.00 $80.00K
YoY Change -100.0% -100.0% -58.12%
Total Long-Term Liabilities $0.00 $0.00 $14.70M
YoY Change -100.0% -100.0% 7596.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.879M $9.575M $15.18M
Total Long-Term Liabilities $0.00 $0.00 $14.70M
Total Liabilities $33.68M $38.96M $69.21M
YoY Change -49.81% -43.7% 212.67%
SHAREHOLDERS EQUITY
Retained Earnings -$347.4M -$344.9M -$208.3M
YoY Change 39.71% 65.63% 57.79%
Common Stock $373.2M $372.8M $367.4M
YoY Change 0.99% 1.49% 1.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.81M $27.89M $159.1M
YoY Change
Total Liabilities & Shareholders Equity $59.49M $66.86M $228.3M
YoY Change -68.35% -70.72% -8.8%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$2.416M -$6.950M -$22.70M
YoY Change -94.02% -69.38% 49.65%
Depreciation, Depletion And Amortization $60.00K $57.00K $1.363M
YoY Change -95.73% -95.82% 121.63%
Cash From Operating Activities -$5.260M -$9.157M -$15.84M
YoY Change -72.45% -42.19% -33.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$894.0K
YoY Change -100.0% -100.0% -67.92%
Acquisitions
YoY Change
Other Investing Activities $20.00K $1.270M $0.00
YoY Change -100.0%
Cash From Investing Activities $20.00K $1.270M -$894.0K
YoY Change -106.1% -242.06% -67.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 4.000K 14.77M
YoY Change -100.0% -99.97% 809.23%
NET CHANGE
Cash From Operating Activities -5.260M -9.157M -15.84M
Cash From Investing Activities 20.00K 1.270M -894.0K
Cash From Financing Activities 0.000 4.000K 14.77M
Net Change In Cash -5.240M -7.883M -1.958M
YoY Change -72.96% 302.6% -92.14%
FREE CASH FLOW
Cash From Operating Activities -$5.260M -$9.157M -$15.84M
Capital Expenditures $0.00 $0.00 -$894.0K
Free Cash Flow -$5.260M -$9.157M -$14.94M
YoY Change -71.97% -38.73% -28.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001733257
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40227
dei Entity Registrant Name
EntityRegistrantName
FINCH THERAPEUTICS GROUP, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3433558
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
229-6499
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
FNCH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1604761
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34051000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71038000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2448000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3369000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
36499000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
74551000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
732000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27308000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q2 fnch In Process Research And Development
InProcessResearchAndDevelopment
0
CY2022Q4 fnch In Process Research And Development
InProcessResearchAndDevelopment
32900000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2318000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2568000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4232000
CY2023Q2 us-gaap Assets
Assets
66857000
CY2022Q4 us-gaap Assets
Assets
162939000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
432000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1097000
CY2023Q2 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7487000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1656000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9575000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14689000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3461000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14653000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29388000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
170000
CY2023Q2 us-gaap Liabilities
Liabilities
38963000
CY2022Q4 us-gaap Liabilities
Liabilities
67228000
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1604761
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1604761
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1601717
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1601717
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
372830000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371350000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-344938000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275641000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27894000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66857000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162939000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
361000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
715000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
361000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
715000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13923000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7199000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29453000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8877000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8164000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18494000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17568000
CY2023Q2 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2022Q2 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
801000
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
903000
us-gaap Restructuring Charges
RestructuringCharges
4037000
us-gaap Restructuring Charges
RestructuringCharges
903000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9881000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
22990000
us-gaap Operating Expenses
OperatingExpenses
75771000
us-gaap Operating Expenses
OperatingExpenses
47924000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9881000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22629000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75664000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47209000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
420000
CY2022Q2 us-gaap Investment Income Net
InvestmentIncomeNet
-65000
us-gaap Investment Income Net
InvestmentIncomeNet
845000
us-gaap Investment Income Net
InvestmentIncomeNet
-52000
CY2023Q2 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
752000
CY2022Q2 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
752000
fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
754000
CY2022Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
617000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1005000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2058000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2931000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-71000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2906000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-58000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6950000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22700000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72758000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47267000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3461000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22700000
us-gaap Net Income Loss
NetIncomeLoss
-69297000
us-gaap Net Income Loss
NetIncomeLoss
-47267000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6950000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22700000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69297000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-47267000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.31
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-43.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-43.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-29.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-29.82
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604795
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604795
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1585978
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1585978
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1603811
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1603811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1585093
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1585093
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
202224000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24567000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
179791000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
61000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
110000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1830000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22700000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
159092000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-62347000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34544000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
300000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27894000
us-gaap Profit Loss
ProfitLoss
-69297000
us-gaap Profit Loss
ProfitLoss
-47267000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1424000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2694000
us-gaap Share Based Compensation
ShareBasedCompensation
1480000
us-gaap Share Based Compensation
ShareBasedCompensation
3950000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
752000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
617000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
fnch Non Cash Interest Expense
NonCashInterestExpense
1939000
fnch Non Cash Interest Expense
NonCashInterestExpense
1003000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3461000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-144000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-320000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-921000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4858000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4033000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-308000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-664000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2431000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2676000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-506000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-50000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
50000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2369000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
5246000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22538000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41485000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1270000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1803000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1256000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1803000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
185000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
14738000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
1155000
fnch Payment Of Terminal Fee Obligation And Prepayment Fee
PaymentOfTerminalFeeObligationAndPrepaymentFee
0
fnch Principal Payments On Capital Lease Obligation
PrincipalPaymentsOnCapitalLeaseObligation
11000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
132000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14780000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37437000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28508000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73805000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135965000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36369000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
107457000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
88000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
37094000
fnch Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
0
fnch Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
7736000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34051000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104673000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2318000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
2784000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36369000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
107457000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34100000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
30
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
32900000
CY2023Q1 fnch Decrease In Accounts Payable And Research And Development Expenses
DecreaseInAccountsPayableAndResearchAndDevelopmentExpenses
1600000
CY2023Q1 fnch Reduction In Accumulated Deficit
ReductionInAccumulatedDeficit
1600000
CY2023Q1 fnch Error Correction Impact
ErrorCorrectionImpact
1600000
CY2023Q1 fnch Error Correction Impact
ErrorCorrectionImpact
1592000
CY2023Q2 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2022Q4 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
978000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
25222000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
246000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9286000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
732000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15936000
us-gaap Depreciation
Depreciation
1400000
us-gaap Depreciation
Depreciation
2700000
CY2023Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
13100000
CY2023Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
800000
CY2015Q4 fnch Lessee Operating Lease Leases Area
LesseeOperatingLeaseLeasesArea
25785
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27308000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32752000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1656000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3431000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29388000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34255000
CY2023Q2 fnch Lease Liabilities
LeaseLiabilities
31044000
CY2022Q4 fnch Lease Liabilities
LeaseLiabilities
37686000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1678000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1311000
us-gaap Operating Lease Cost
OperatingLeaseCost
3405000
us-gaap Operating Lease Cost
OperatingLeaseCost
1650000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
31000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
139000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
87000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
469000
us-gaap Variable Lease Cost
VariableLeaseCost
532000
us-gaap Variable Lease Cost
VariableLeaseCost
964000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
959000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
0
us-gaap Sublease Income
SubleaseIncome
1919000
us-gaap Sublease Income
SubleaseIncome
0
CY2023Q2 us-gaap Lease Cost
LeaseCost
810000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1811000
us-gaap Lease Cost
LeaseCost
2035000
us-gaap Lease Cost
LeaseCost
2753000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2369000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
5246000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1825000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4795000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4930000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
5071000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
5215000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
22391000
CY2023Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
44227000
CY2023Q2 fnch Interest Portion Of Operating Leases Future Minimum Payments Due
InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
-13183000
CY2023Q2 fnch Present Value Of Future Minimum Lease Payments
PresentValueOfFutureMinimumLeasePayments
31044000
CY2023Q2 fnch Accrued Research And Development
AccruedResearchAndDevelopment
99000
CY2022Q4 fnch Accrued Research And Development
AccruedResearchAndDevelopment
1967000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4945000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5852000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1482000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
880000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
961000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1462000
CY2023Q2 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
7487000
CY2022Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
10161000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
800000
us-gaap Restructuring Charges
RestructuringCharges
4000000.0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
72586
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
118564
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1830000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1480000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3950000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22700000
us-gaap Net Income Loss
NetIncomeLoss
-69297000
us-gaap Net Income Loss
NetIncomeLoss
-47267000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6950000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6950000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22700000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-22700000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69297000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69297000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47267000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-47267000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604795
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604795
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1585978
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1585978
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1603811
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1603811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1585093
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1585093
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.31
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-43.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-43.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-29.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-29.82
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
72586
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
118564

Files In Submission

Name View Source Status
0000950170-23-040924-index-headers.html Edgar Link pending
0000950170-23-040924-index.html Edgar Link pending
0000950170-23-040924.txt Edgar Link pending
0000950170-23-040924-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fnch-20230630.htm Edgar Link pending
fnch-20230630.xsd Edgar Link pending
fnch-ex10_5.htm Edgar Link pending
fnch-20230630_cal.xml Edgar Link unprocessable
fnch-20230630_def.xml Edgar Link unprocessable
fnch-20230630_lab.xml Edgar Link unprocessable
fnch-20230630_pre.xml Edgar Link unprocessable
fnch-20230630_htm.xml Edgar Link completed
fnch-ex10_6.htm Edgar Link pending
fnch-ex10_7.htm Edgar Link pending
fnch-ex31_1.htm Edgar Link pending
fnch-ex31_2.htm Edgar Link pending
fnch-ex32_1.htm Edgar Link pending
img120795611_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable